SecBot SecBot
SECBOTREPLAY Home › Report › PULM

PULM · Pulmatrix filed Amendment No

Pulmatrix, Inc. · S-4/A filed Sep 4, 2026 at 17:29 ET

At the news

BEARISHIMPACT 7/10

S-4/A filed Sep 4, 2026 at 17:29 ET

Pulmatrix filed Amendment No. 2 to its S-4 registration statement, advancing the proposed reverse merger with Eos SENOLYTIX. The filing sets a special stockholder meeting for October 2, 2026, to vote on key proposals including share issuance for the merger (which would dilute current PULM holders to ~6% of the combined company), a reverse stock split, and an authorized share increase. The merger is a transformative event that will effectively transfer control to Eos, with the combined company to be renamed Eos SENOLYTIX Inc. and trade under 'MTXL', but existing PULM holders face massive dilution and the combined entity is a pre-revenue biotech with significant execution risk.

  • Pulmatrix stockholders will own approximately 6% of the combined company post-merger, with Eos securityholders owning ~94%.
  • The special meeting is scheduled for October 2, 2026, to vote on the merger, reverse stock split (1:2 to 1:10), and authorized share increase from 200M to 250M shares.
  • Eos must receive at least $13M in gross cash proceeds from financing transactions as a condition to closing.
  • The combined company will be a 'controlled company' with SENOTHERAPEUTIX, Inc. expected to own >50% voting power.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access